Results 241 to 250 of about 1,479,889 (356)

Long-term Anticoagulant Treatment in Ischemic Heart Disease : Symposium on Coronary Heart Diseases and Anticoagulants

, 1963
Mototaka Murakami
openalex   +2 more sources

Increased Thrombogenicity is Associated With Coronary Microvascular Dysfunction in Patients With STEMI—A Proof‐of‐Concept Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Up to 50% of patients with ST‐segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) develop coronary microvascular dysfunction (CMD). Aims This study aims to assess whether a prothrombotic state of coronary blood, defined by thromboelastography (TEG), is associated with post ...
Roberto Scarsini, Denis Leonardi, Andrea Bottardi, Concetta Mammone, Leonardo Portolan, Caterina Butturini, Verdiana Galli, Francesco Della Mora, Alessandro Ruzzarin, Sara Pazzi, Anna Piccoli, Simone Fezzi, Domenico Tavella, Gabriele Pesarini, Leonardo Gottin, Flavio Ribichini   +15 more
wiley   +1 more source

The Implementation Gap: A Qualitative Analysis of Determinants of Sexual Counseling Among Coronary Heart Disease Patients in China. [PDF]

Patient Prefer Adherence
Zhang F, Li Y, Yang W, Fan Y, Wang A.
europepmc   +1 more source

Early descriptions of the clinical syndrome of coronary heart disease

, 1965
Yang Wang
openalex   +1 more source

The First‐in‐Man Technique of Drug Eluting and Perfusion Therapy for Left Main Coronary Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Treating ostial left circumflex artery (LCx) lesions in percutaneous coronary intervention (PCI) for left main disease (LMD) remains a challenge. Despite recent recommendations for the use of drug‐coated balloon (DCB) in this lesion, there are concerns about crossover‐stenting from the left main trunk (LMT) to the left anterior ...
Takayuki Warisawa, Yoshiki Kawai, Takuya Matsumoto, Shingo Sato, Makoto Takeyama, Yuta Nakamura, Susumu Katsushika, Aritomo Katsura, Takahiro Sato, Masashiro Matsushita, Jiro Ando   +10 more
wiley   +1 more source

Progress in the study of the mechanism of ferroptosis in coronary heart disease and clinical intervention strategies. [PDF]

Front Cardiovasc Med
Liu Y, Yu Z, Lu Y, Liu Y, Chen L, Li J.
europepmc   +1 more source

(2) Epidemiologic Study of Coronary Heart Disease

, 1968
Tachio Kobayashi
openalex   +2 more sources

Treatment With Phosphodiesterase 5 Inhibitors and Long‐Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long‐term outcomes in patients with cardiovascular disease are not well understood. Objective: We studied the association between PDE5 inhibitor therapy and the incidence of adverse cardiovascular major adverse cardiovascular events (MACE) in patients ...
Sumon Roy, Annette Min, Edward O. McFalls, Robert A. Perera, Fadi N. Salloum, Ion S. Jovin   +5 more
wiley   +1 more source

Effect of thyroid stimulating hormone on the prognosis of coronary heart disease. [PDF]

Front Endocrinol (Lausanne)
Ding N, Hua R, Guo H, Xu Y, Yuan Z, Wu Y, Li T.   +6 more
europepmc   +1 more source

A Case Series of Valve‐in‐Valve Transcatheter Aortic Valve Replacement in Stentless Bioprosthetic Valves Using Self‐Expanding Platform With Minimalist Approach

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Valve‐in‐valve (ViV) Transcatheter aortic valve replacement (TAVR) has emerged as a valid treatment option in symptomatic patients with failed aortic bioprosthetic valves, most especially in those with intermediate, high or prohibitive risk of surgery. Due to the unique design of stentless bioprosthetic valves with absence of visible posts and
Adeogo Akinwale Olusan, Raj Rajendra, Elved Roberts, Jan Kovac   +3 more
wiley   +1 more source